The treatment landscape for NSCLC continues to evolve at a rapid pace with the additions of new therapies and label expansions of current therapies into new patient populations. Examples include the approvals of Alunbrig for ALK-positive metastatic NSCLC,Tafinlar plus Mekinist for BRAF-mutation-positive NSCLC, and Imfinzi for unresectable stage III NSCLC as well as the label expansion of Keytruda in combination with chemotherapy as a first-line regimen for metastatic nonsquamous patients. Our primary research provides insight into the current use of approved therapies for NSCLC in the United States and uncovers key factors that influence medical oncologists’ prescribing decisions in this highly dynamic indication.
Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers.
Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2020
Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becom...
Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China)
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...